Alan Auerbach: Puma Biotech's Overnight Billionaire

Published: Sep 8, 2014
Alan Auerbach: Puma Biotech's Overnight Billionaire
Image: Patrick Welsh for Forbes

Alan Auerbach JUST hit the jackpot. Puma Biotechnology’s stock skyrocketed 295 percent on July 23 following good news from a Phase III clinical trial of an experimental breast cancer drug that Puma licensed from Pfizer. In a trial of 2,821 women with early-stage HER2-positive breast cancer, the drug, Neratinib, improved disease-free survival by 33 percent compared to a placebo. Puma intends to apply for regulatory approval in the first half of 2015. “We are looking forward to getting this drug to patients,” says Auerbach, Puma’s CEO.

Auerbach, 44, has another reason to be happy: The astounding stock jump made him an overnight billionaire. Auerbach founded Puma in 2010 and owns nearly 20 percent of the firm, including 2.1 million warrants and 230,000 exercisable options. At the July 23 closing price of $233, Auerbach’s stake was worth over $1.3 billion. Then the stock fell 14 percent over two days, closing at $200.68. Prior to Puma, Auerbach founded Cougar Biotechnology, which was bought by Johnson & Johnson in 2009 for $1 billion. He started his career as a research analyst at Wells Fargo, covering biotech firms. Auerbach received a BS in biomedical engineering from Boston University and an MS from the University of Southern California. Puma Biotechnology is headquartered in Los Angeles.

(This story appears in the 19 September, 2014 issue of Forbes India. You can buy our tablet version from Magzter.com. To visit our Archives, click here.)

Show More
Post Your Comment
Required
Required, will not be published
All comments are moderated
How the Numbers Stack Up in Prime-Time's Biggest Shows
'Clients Now are Willing to Pay for Investment Advice'